Immunology, infectious diseases and specialty care

In Immunology and Inflammation, our core focus is on chronic, immunologically-mediated and inflammatory-driven diseases.

19

new immunology and infectious diseases compounds in clinical development

45%

of R&D pipeline externally sourced

We focus on innovative scientific mechanisms that have the potential to translate to products that are first-in-class or best-in-class and/or best-in-disease. Our therapeutic areas of focus include rheumatologic, respiratory, and gastrointestinal diseases. Molecules that can strategically complement our existing strong franchises in these areas are given priority. We prioritise programmes that have strong target biology and human translational evidence in three areas of biology: Innate Immunity, Adaptive Immunity and Tissue Inflammation / Fibrosis.

In Infectious Diseases, our focus is on Hepatitis B (HBV), influenza and multidrug resistant (MDR) antibacterials. For hepatitis B, we are looking for any products or therapeutic strategies that can promote durable seroconversion. While these indications are key to Roche, we are also seeking innovative, best-in-class treatments for chronic or non-chronic viral infections with high unmet need such as RSV and other respiratory infections. We prioritise products with robust clinical proof of concept and/or clinical differentiation.

Lastly, our Specialty Care focus covers chronic diseases with an infectious, immunologic or inflammatory-mediated pathophysiology which are treated by specialist healthcare professionals and targeted by a focused sales force, and which complement our existing Roche franchises.

Meet the scientists

Lu, a virologist at our Shanghai site, researches anti-viral molecules for the treatment of the hepatitis B virus.

If you have a promising drug candidate in these areas, why not get in touch with us.

Partner with us

roche.com partnering contact

Shehnaaz Suliman Head of Immunology, Infectious Diseases and Specialty Care Partnering

roche.com partnering

If you have an idea, we would like to hear from you.

Contact us